Floatz logo

.Alpha.-1 Protease Inhibitor

Pulmonary Emphysema

Sanofiprotein_peptidePhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Pulmonary Emphysema cohort.

Asset / SponsorPhaseRating
Alpha-1-Proteinase Inhibitor
CSL Behring
Phase 4BBB
ce1226
CSL Behring
Phase 4BB
Kamada-Aat For Inhalation
Kamada, Ltd.
Phase 2/3B
Aspirin
Columbia University
Phase 2B
Hyaluronic Acid Inhalation
Gerard Turino
Phase 2B

View all 13 →

Same molecule, other indications

.Alpha.-1 Protease Inhibitor is also rated in:

alpha 1-antitrypsin deficiencyActive
A
Indicative · Phase 4
81 / 100
View asset →
chronic obstructive pulmonary diseaseActive
BB
Indicative · Phase 4
65 / 100
View asset →
type 1 diabetes mellitusDormant
B
Indicative · Phase 2
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →